Navigation Links
Clinical Data & Innovation Will Shift PCI and CABG Procedures in Europe
Date:5/14/2009

By 2013, over 685,000 PCI and 165,000 CABG procedures will be performed, according to Millennium Research Group

WALTHAM, Mass., May 14 /PRNewswire/ -- According to two new Millennium Research Group (MRG) reports, emerging clinical data and innovations in device technology will shift the balance between percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG) procedures for unique subgroups with coronary artery disease through 2013. MRG's European Markets for Interventional Cardiology Devices 2009 and European Markets for Coronary Artery Bypass Graft Devices 2009 reports indicate that by 2013, over 685,000 PCI procedures and over 165,000 CABG procedures will be performed across Europe.

Results of clinical studies supporting the benefits of PCI will expand the eligible patient population to include higher-risk subgroups, which until recently have been untreated by PCI. In 2008, results of the CARDia trial identified similar rates of myocardial infarction, stroke, or death at 12 months in diabetic patients who received either PCI or CABG surgery. Initial results of the SYNTAX trial found the same trend for patients with complicated forms of CAD. Consequently, while CABG surgery will remain the gold standard treatment for complex CAD, some of these patients may now be considered eligible for PCI.

"Results of recent clinical studies demonstrate that PCI can be used to treat patients with significantly more complicated forms of CAD than previously thought possible," says Anuk Karunaratne, Senior Analyst at MRG. "Innovations in PCI technology -- such as improved stent design and intravascular ultrasound (IVUS) -- will enable treatment of more complicated cases and will allow PCI use to expand further into CABG territory, although it's unlikely that referral patterns will shift significantly in the short-term. Nevertheless, continued innovation and clinical data will influence physicians to select PCI as the optimal treatment for some higher-risk patients."

MRG's new reports, European Markets for Interventional Cardiology Devices 2009 and European Markets for Coronary Artery Bypass Graft (CABG) Devices 2009 cover France, Germany, Italy and the UK, and also provide data such as usage rates, units per procedure, average selling prices, and growth rates. Detailed market shares are provided across all market segments for key companies, including Abbott Vascular, Boston Scientific, Johnson & Johnson's Cordis, Medtronic, Sorin Group, Terumo Medical, Volcano, and more.

About Millennium Research Group

Millennium Research Group (www.MRG.net), a Decision Resources, Inc. company (www.DecisionResourcesInc.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the health care sector. The company provides specialized industry expertise through syndicated reports, ongoing Marketrack(TM) projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the health care industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Amy Krohn
    Millennium Research Group
    416-364-7776 x101
    akrohn@mrg.net

    Elizabeth Marshall
    Decision Resources Inc.
    781-296-2563
    emarshall@dresources.com


'/>"/>
SOURCE Millennium Research Group
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Radiologists encouraged to look beyond cancer for clinically unseen diseases
2. Clinical depression linked to abnormal emotional brain circuits
3. Preclinical study suggests organ-transplant drug may aid in lupus fight
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Good Clinical Practice Journal Awards: Winners Announced
6. Microsoft Helps Developers of Clinical User Interfaces Improve Efficiency, Patient Safety With Free Toolkit
7. Study Questions Dead-End Cancer Clinical Trials
8. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
9. Clinical trials present better alternatives for dialysis patients
10. Mirixa Debuts New Clinical Technology Solutions for Enhancing Patient Care
11. IMPACT initiative looks to improve patient participation in clinical trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... February 27, 2017 , ... Texas ... week. In addition, Discount Power's RCE (Residential Customer Equivalent) count exceeds 150,000. ... The company had 800 customers and 2,250 RCEs at the time of acquisition. ...
(Date:2/27/2017)... Francisco, CA (PRWEB) , ... February 27, 2017 ... ... clinic serving San Francisco and environs, is proud to announce an upgrade to ... information on the upgraded Yelp page on topics as diverse as Platelet Rich ...
(Date:2/26/2017)... ... February 26, 2017 , ... Today, A' Design Awards ... of International Social Design Awards. , The 7th A' Social Design Award ... and Institutions worldwide with realized projects and conceptual works. , The first phase ...
(Date:2/26/2017)... York, New York (PRWEB) , ... February 26, ... ... luxury baby products for wholesale distribution in North America, today announced it would ... online sites. The company, which prides itself on crafting quality and unique baby ...
(Date:2/26/2017)... ... 2017 , ... ODH, Inc.™ announced today it will exhibit and speak ... City Hotel in Arlington, VA. ODH’s director of medical strategy, Candace Saldarini, M.D., will ... Medicaid population health management. , ODH will also have an exhibit booth where attendees ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... , Feb. 24, 2017 Juan Monteverde ... Associates PC , a boutique securities firm headquartered at ... City , announces that a class action lawsuit ... Massachusetts  against Inotek Pharmaceuticals Corporation (NASDAQ:  ITEK)("Inotek" ... Company,s securities between July 23, 2015 and December 30, 2016, ...
(Date:2/24/2017)... MELBOURNE , Australien, 24. Februar 2017 /PRNewswire/ ... innovatives, diversifiziertes Unternehmen des Gesundheitsbereiches, ist erfreut, für ... Vergleich mit dem entsprechenden Vorjahreszeitraum exzellente Ergebnisse vorlegen ... BioMedical und Aktualisierung zum Wachstum" finden Sie ... Gewinn nach Steuern 2,12 Millionen USD (Dez. 2015: ...
(Date:2/24/2017)... NEW YORK , Feb. 23, 2017  This ... US$ Thousand by the following Products: ... analyzed in the report include Pharmaceuticals, and Agrochemicals. The ... Japan , Europe , ... provided for the period 2015 through 2022. Also, a ...
Breaking Medicine Technology: